D. Rossi and G. Gaidano, Lymphocytosis and ibrutinib treatment of CLL, Blood, vol.123, issue.12, pp.1772-1776, 2014.

O. C. Bruton, Agammaglobulinemia. Pediatrics, vol.9, issue.6, pp.722-730, 1952.

L. A. Honigberg, A. M. Smith, M. Sirisawad, E. Verner, D. Loury et al., The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy, Proceedings of the National Academy of Sciences of the United States of America, vol.107, issue.29, pp.13075-80, 2010.

R. H. Advani, J. J. Buggy, J. P. Sharman, S. M. Smith, T. E. Boyd et al., Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol.31, issue.1, pp.88-94, 2013.

M. L. Wang, S. Rule, P. Martin, A. Goy, R. Auer et al., Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. The New England journal of medicine, vol.369, pp.507-523, 2013.

S. Inman, FDA Approves Ibrutinib for Mantle Cell Lymphoma: OncLive, 2013.

J. C. Byrd, J. R. Brown, S. O'brien, J. C. Barrientos, N. E. Kay et al., Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England journal of medicine, vol.371, pp.213-236, 2014.

J. A. Burger, A. Tedeschi, P. M. Barr, T. Robak, C. Owen et al., Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. The New England journal of medicine, vol.373, pp.2425-2462, 2015.

M. Dreyling, W. Jurczak, M. Jerkeman, R. S. Silva, C. Rusconi et al., Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study, Lancet, vol.387, pp.770-778, 2016.

A. Noy, S. De-vos, C. Thieblemont, P. Martin, C. R. Flowers et al., Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma, Blood, vol.129, issue.16, pp.2224-2256, 2017.

S. P. Treon, C. K. Tripsas, K. Meid, D. Warren, G. Varma et al., Ibrutinib in previously treated Waldenstrom's macroglobulinemia. The New England journal of medicine, vol.372, pp.1430-1470, 2015.

D. Miklos, C. S. Cutler, M. Arora, E. K. Waller, M. Jagasia et al., Ibrutinib for chronic graft-versus-host disease after failure of prior therapy, Blood, vol.130, issue.21, pp.2243-50, 2017.

, Résumédes Caractéristiques du Produit -USA

. Résumé-des-caractéristiques-du-produit--france,

J. C. Byrd, R. R. Furman, S. E. Coutre, I. W. Flinn, J. A. Burger et al., Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. The New England journal of medicine, vol.369, pp.32-42, 2013.

J. C. Byrd, R. R. Furman, S. E. Coutre, J. A. Burger, K. A. Blum et al., Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib, Blood, vol.125, issue.16, pp.2497-506, 2015.

F. Caron, D. P. Leong, C. Hillis, G. Fraser, and D. Siegal, Current understanding of bleeding with ibrutinib use: a systematic review and meta-analysis. Blood advances, vol.1, pp.772-780, 2017.

A. H. Lipsky, M. Z. Farooqui, X. Tian, S. Martyr, A. M. Cullinane et al., Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib, Haematologica, vol.100, issue.12, pp.1571-1579, 2015.

R. A. Rigg, J. E. Aslan, L. D. Healy, M. Wallisch, M. L. Thierheimer et al., Oral administration of Bruton's tyrosine kinase inhibitors impairs GPVImediated platelet function, American journal of physiology Cell physiology, vol.310, issue.5, pp.373-80, 2016.

D. P. Leong, F. Caron, C. Hillis, A. Duan, J. S. Healey et al., The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis, Blood, vol.128, issue.1, pp.138-178, 2016.

S. Yun, N. D. Vincelette, U. Acharya, and I. Abraham, Risk of Atrial Fibrillation and Bleeding Diathesis Associated With Ibrutinib Treatment: A Systematic Review and Pooled Analysis of Four Randomized Controlled Trials. Clinical lymphoma, myeloma & leukemia, vol.17, pp.31-38, 2017.

J. R. Mcmullen, E. J. Boey, J. Y. Ooi, J. F. Seymour, M. J. Keating et al., Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling, Blood, vol.124, issue.25, pp.3829-3859, 2014.

J. R. Mcmullen, F. Amirahmadi, E. A. Woodcock, M. Schinke-braun, R. D. Bouwman et al., Protective effects of exercise and phosphoinositide 3-kinase(p110alpha) signaling in dilated and hypertrophic cardiomyopathy, p.35

, Proceedings of the National Academy of Sciences of the United States of America, vol.104, issue.2, pp.612-619, 2007.

L. Pretorius, X. J. Du, E. A. Woodcock, H. Kiriazis, R. C. Lin et al., Reduced phosphoinositide 3-kinase (p110alpha) activation increases the susceptibility to atrial fibrillation. The American journal of pathology, vol.175, pp.998-1009, 2009.

S. P. Mulligan, C. M. Ward, D. Whalley, and S. N. Hilmer, Atrial fibrillation, anticoagulant stroke prophylaxis and bleeding risk with ibrutinib therapy for chronic lymphocytic leukaemia and lymphoproliferative disorders, British journal of haematology, vol.175, issue.3, pp.359-64, 2016.

J. R. Brown, J. Moslehi, S. O'brien, P. Ghia, P. Hillmen et al., Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials, Haematologica, vol.102, issue.10, pp.1796-805, 2017.

T. E. Wiczer, L. B. Levine, J. Brumbaugh, J. Coggins, Q. Zhao et al., Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib, Blood advances, vol.1, issue.20, pp.1739-1787, 2017.

P. A. Thompson, V. Levy, C. S. Tam, A. Nawakil, C. Goudot et al., Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study, British journal of haematology, vol.175, issue.3, pp.462-468, 2016.

, Ibrutinib for relapsed/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients, Haematologica, vol.101, issue.12, pp.1563-72, 2016.

D. Cardinale, A. Martinoni, C. M. Cipolla, M. Civelli, G. Lamantia et al., Atrial fibrillation after operation for lung cancer: clinical and prognostic significance. The Annals of thoracic surgery, vol.68, pp.1827-1858, 1999.

D. Farmakis, J. Parissis, and G. Filippatos, Insights into onco-cardiology: atrial fibrillation in cancer, Journal of the American College of Cardiology, vol.63, issue.10, pp.945-53, 2014.

P. Prandoni, A. W. Lensing, A. Piccioli, E. Bernardi, P. Simioni et al., Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis, Blood, vol.100, issue.10, pp.3484-3492, 2002.

J. F. Timp, S. K. Braekkan, H. H. Versteeg, and S. C. Cannegieter, Epidemiology of cancer-associated venous thrombosis, Blood, vol.122, issue.10, pp.1712-1735, 2013.

A. Asnani, A. Manning, M. Mansour, J. Ruskin, E. P. Hochberg et al., Management of atrial fibrillation in patients taking targeted cancer therapies, Cardio-Oncology, vol.3, issue.1, 2017.

P. Kirchhof, S. Benussi, D. Kotecha, A. Ahlsson, D. Atar et al., ESC Guidelines for the Management of Atrial Fibrillation Developed in Collaboration With EACTS, Revista espanola de cardiologia, vol.70, issue.1, p.50, 2016.

C. T. January, L. S. Wann, J. S. Alpert, H. Calkins, J. E. Cigarroa et al., AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society, Journal of the American College of Cardiology, vol.64, issue.21, pp.1-76, 2014.

J. L. Zamorano, P. Lancellotti, D. R. Munoz, V. Aboyans, R. Asteggiano et al., , 2016.

, Kardiologia polska, vol.74, issue.11, pp.1193-233, 2016.

G. Y. Lip, R. Nieuwlaat, R. Pisters, D. A. Lane, and H. J. Crijns, Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation, Chest, vol.137, issue.2, pp.263-72, 2010.

R. Pisters, D. A. Lane, R. Nieuwlaat, C. B. De-vos, H. J. Crijns et al., A novel userfriendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey, Chest, vol.138, issue.5, pp.1093-100, 2010.

T. D. Shanafelt, S. A. Parikh, P. A. Noseworthy, V. Goede, K. G. Chaffee et al., Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL)

, Leukemia & lymphoma, vol.58, issue.7, pp.1630-1639, 2017.

P. Lancellotti, C. Tribouilloy, A. Hagendorff, B. A. Popescu, T. Edvardsen et al., Recommendations for the echocardiographic assessment of native valvular regurgitation: an executive summary from the European Association of Cardiovascular Imaging, European heart journal cardiovascular Imaging, vol.14, issue.7, pp.611-655, 2013.

H. Baumgartner, J. Hung, J. Bermejo, J. B. Chambers, A. Evangelista et al., Echocardiographic assessment of valve stenosis: EAE/ASE recommendations for clinical practice, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography, vol.22, issue.1, pp.101-103, 2009.

M. Galderisi, B. Cosyns, T. Edvardsen, N. Cardim, V. Delgado et al., Standardization of adult transthoracic echocardiography reporting in agreement with recent chamber quantification, diastolic function, and heart valve disease recommendations: an expert consensus document of the European Association of Cardiovascular Imaging, European heart journal cardiovascular Imaging, vol.18, issue.12, pp.1301-1311, 2017.

T. Wilke, A. Groth, S. Mueller, M. Pfannkuche, F. Verheyen et al., Incidence and prevalence of atrial fibrillation: an analysis based on 8.3 million 37 patients. Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the, European Society of Cardiology, vol.15, issue.4, pp.486-93, 2013.

, Prise en charge de l'hypertension artérielle de l'adulteRecommandations, Common Terminology Criteria for Adverse Events (CTCAE) v5.0

M. Escudier, J. Cautela, N. Malissen, Y. Ancedy, M. Orabona et al., Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor-Related Cardiotoxicity, Circulation, vol.136, issue.21, pp.2085-2092, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01729764

, Nombre de publications cardio

G. Reda, B. Fattizzo, R. Cassin, V. Mattiello, T. Tonella et al., Predictors of atrial fibrillation in ibrutinib-treated CLL patients: a prospective study, Journal of hematology & oncology, vol.11, issue.1, p.79, 2018.

P. D. Ziegler, J. L. Koehler, and R. Mehra, Comparison of continuous versus intermittent monitoring of atrial arrhythmias, Heart rhythm, vol.3, issue.12, pp.1445-52, 2006.

A. M. Sinha, H. C. Diener, C. A. Morillo, T. Sanna, R. A. Bernstein et al., Cryptogenic Stroke and underlying Atrial Fibrillation (CRYSTAL AF): design and rationale, American heart journal, vol.160, issue.1, pp.36-41, 2010.

F. D. Hobbs, D. A. Fitzmaurice, J. Mant, E. Murray, S. Jowett et al., A randomised controlled trial and cost-effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in people aged 65 and over. The SAFE study, Health technology assessment, vol.9, issue.40, pp.1-74, 2005.

E. J. Benjamin, D. Levy, S. M. Vaziri, D. 'agostino, R. B. Belanger et al., Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study, Jama, vol.271, issue.11, pp.840-844, 1994.

A. Alonso, B. P. Krijthe, T. Aspelund, K. A. Stepas, M. J. Pencina et al., Simple risk model predicts incidence of atrial fibrillation in a racially and geographically diverse population: the CHARGE-AF consortium, Journal of the American Heart Association, vol.2, issue.2, p.102, 2013.

R. Pfister, J. Bragelmann, G. Michels, N. J. Wareham, R. Luben et al., Performance of the CHARGE-AF risk model for incident atrial fibrillation in the 38

. Epic-norfolk-cohort, European journal of preventive cardiology, vol.22, issue.7, pp.932-941, 2015.

D. G. Wyse, A. L. Waldo, J. P. Dimarco, M. J. Domanski, Y. Rosenberg et al., A comparison of rate control and rhythm control in patients with atrial fibrillation. The New England journal of medicine, vol.347, pp.1825-1858, 2002.

D. L. Packer, D. B. Mark, R. A. Robb, K. H. Monahan, T. D. Bahnson et al., Catheter Ablation versus Antiarrhythmic Drug Therapy for Atrial Fibrillation (CABANA) Trial: Study Rationale and Design, American heart journal, vol.199, pp.192-201, 2018.

Y. Wasserstrum, P. Raanani, R. Kornowski, and Z. Iakobishvili, Concomitant Treatment with Ibrutinib and Amiodarone Causing Reversible Heart Failure Syndrome, The Israel Medical Association journal : IMAJ, vol.18, issue.7, pp.433-437, 2016.

Y. F. Hu, C. J. Liu, P. M. Chang, H. M. Tsao, Y. J. Lin et al., Incident thromboembolism and heart failure associated with new-onset atrial fibrillation in cancer patients, International journal of cardiology, vol.165, issue.2, pp.355-362, 2013.

A. Y. Lee, M. N. Levine, R. I. Baker, C. Bowden, A. K. Kakkar et al., Lowmolecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. The New England journal of medicine, vol.349, pp.146-53, 2003.

R. D. Hull, G. F. Pineo, R. F. Brant, A. F. Mah, N. Burke et al., Long-term lowmolecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. The American journal of medicine, vol.119, pp.1062-72, 2006.

S. R. Deitcher, C. M. Kessler, G. Merli, J. R. Rigas, R. M. Lyons et al., Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period, hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, vol.12, issue.4, pp.389-96, 2006.

Y. J. Lee, J. K. Park, J. S. Uhm, J. Y. Kim, H. N. Pak et al., Bleeding risk and major adverse events in patients with cancer on oral anticoagulation therapy, International journal of cardiology, vol.203, pp.372-380, 2016.

C. B. Granger, J. H. Alexander, J. J. Mcmurray, R. D. Lopes, E. M. Hylek et al., Apixaban versus warfarin in patients with atrial fibrillation. The New England journal of medicine, vol.365, pp.981-92, 2011.

M. R. Patel, K. W. Mahaffey, J. Garg, G. Pan, D. E. Singer et al., Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. The New England journal of medicine, vol.365, pp.883-91, 2011.
URL : https://hal.archives-ouvertes.fr/hal-01038111

S. J. Connolly, M. D. Ezekowitz, S. Yusuf, J. Eikelboom, J. Oldgren et al., Dabigatran versus warfarin in patients with atrial fibrillation. The New England journal of medicine, vol.361, pp.1139-51, 2009.

S. Shah, F. L. Norby, Y. H. Datta, P. L. Lutsey, R. F. Maclehose et al., Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation, Blood advances, vol.2, issue.3, pp.200-209, 2018.

A. G. Ording, E. Horvath-puho, K. Adelborg, L. Pedersen, P. Prandoni et al., Thromboembolic and bleeding complications during oral anticoagulation therapy in cancer patients with atrial fibrillation: a Danish nationwide population-based cohort study. Cancer medicine, vol.6, pp.1165-72, 2017.

N. J. Short and J. M. Connors, New oral anticoagulants and the cancer patient, The oncologist, vol.19, issue.1, pp.82-93, 2014.

H. D. Finnes, K. G. Chaffee, T. G. Call, W. Ding, S. S. Kenderian et al., Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice, Leukemia & lymphoma, vol.58, issue.6, pp.1376-83, 2017.

L. Kazianka, C. Drucker, C. Skrabs, W. Thomas, T. Melchardt et al., Ristocetin-induced platelet aggregation for monitoring of bleeding tendency in CLL treated with ibrutinib, Leukemia, vol.31, issue.5, pp.1117-1139, 2017.

J. R. Brown, J. Moslehi, M. S. Ewer, S. M. O'brien, P. Ghia et al., Incidence of and Risk Factors for Major Hemorrhage in Patients Treated with Ibrutinib: Results from an Integrated Analysis, vol.130, pp.1743-74, 2017.

N. Wallace, E. Wong, D. Cooper, and H. Chao, A case of new-onset cardiomyopathy and ventricular tachycardia in a patient receiving ibrutinib for relapsed mantle cell lymphoma, Clinical case reports, vol.4, issue.12, pp.1120-1121, 2016.

B. L. Lampson, L. Yu, R. J. Glynn, J. C. Barrientos, E. D. Jacobsen et al., Ventricular arrhythmias and sudden death in patients taking ibrutinib, Blood, vol.129, issue.18, pp.2581-2585, 2017.

T. Nassif, J. Banchs, S. W. Yusuf, and E. Mouhayar, Acute haemorrhagic tamponade in cancer patients receiving direct oral anticoagulant: case series, European Heart Journal -Case Reports, vol.1, issue.2, pp.1-4, 2017.

J. C. Byrd, B. Harrington, S. O'brien, J. A. Jones, A. Schuh et al., ACP-196) in Relapsed Chronic Lymphocytic Leukemia. The New England journal of medicine, vol.374, pp.323-355, 2016.